Figure 1 demonstrated that the involvement style of FLT3 (seven of the eight cases appeared to be point mutations) was not the same as that of FLT3‐ITD, which is more often observed in de novo AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.